CancerDrs

Prostate Cancer clinical trials in Illinois

34 actively recruiting prostate cancer trials at 60 sites across Illinois.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full prostate cancer transparency page →

Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …

Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Illinois:
  • Alton Memorial Hospital — Alton, Illinois
  • Advocate Outpatient Center - Aurora — Aurora, Illinois
  • Advocate Good Shepherd Hospital — Barrington, Illinois
  • Illinois CancerCare-Bloomington — Bloomington, Illinois
  • Illinois CancerCare-Carthage — Carthage, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Illinois:
  • University of Illinois — Chicago, Illinois
  • Elmhurst Memorial Hospital — Elmhurst, Illinois
  • Edward Hospital/Cancer Center — Naperville, Illinois
  • Edward Hospital/Cancer Center?Plainfield — Plainfield, Illinois
  • Memorial Hospital East — Shiloh, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Illinois:
  • Illinois CancerCare-Bloomington — Bloomington, Illinois
  • Illinois CancerCare-Canton — Canton, Illinois
  • Illinois CancerCare-Carthage — Carthage, Illinois
  • Centralia Oncology Clinic — Centralia, Illinois
  • Rush MD Anderson Cancer Center — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body i…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06470243
Sites in Illinois:
  • Illinois CancerCare-Bloomington — Bloomington, Illinois
  • Illinois CancerCare-Canton — Canton, Illinois
  • Memorial Hospital of Carbondale — Carbondale, Illinois
  • SIH Cancer Institute — Carterville, Illinois
  • Illinois CancerCare-Carthage — Carthage, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or dea…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in Illinois:
  • Duly Health and Care — Lisle, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Illinois:
  • University of Illinois at Chicago ( Site 0105) — Chicago, Illinois
  • University of Chicago Medical Center ( Site 0045) — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06235697
Sites in Illinois:
  • Memorial Hospital East — Shiloh, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).

Sponsor: Amgen
NCT ID: NCT07213674
Sites in Illinois:
  • University of Illinois Chicago — Chicago, Illinois
  • Cancer Care Specialists of Illinois — Decatur, Illinois
  • Midwestern Regional Medical Center dba City of Hope Chicago — Zion, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. Th…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05939414
Sites in Illinois:
  • University of Chicago — Chicago, Illinois
  • The Cancer Institute of Alexian Brothers — Elk Grove, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression f…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06855277
Sites in Illinois:
  • Northwestern University — Chicago, Illinois
  • University of Illinois Cancer Center at Chicago — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in Illinois:
  • University of Chicago — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Federal

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…

Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in Illinois:
  • Edward Hines Jr. VA Hospital, Hines, IL — Hines, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Sponsor: Dendreon
NCT ID: NCT06134232
Sites in Illinois:
  • Associated Urological Specialists — Chicago Ridge, Illinois
  • UroPartners — Glenview, Illinois
  • Advanced Urology Associates — New Lenox, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in comb…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in Illinois:
  • University of Chicago Medical Center — Chicago, Illinois
  • Loyola University Medical Center — Maywood, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use ola…

Sponsor: VA Office of Research and Development
NCT ID: NCT04038502
Sites in Illinois:
  • Jesse Brown VA Medical Center, Chicago, IL — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…

Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Illinois:
  • University of Chicago Medical Center — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

This phase II trial compares the effect of FDG-positron emission tomography (PET)-guided metastasis directed radiation therapy (MDRT) in combination with standard treatments to standard treatments alone in treating patients with prostate c…

Sponsor: Northwestern University
NCT ID: NCT06244004
Sites in Illinois:
  • Northwestern University — Chicago, Illinois
  • Northwestern Medicine: Kishwaukee — DeKalb, Illinois
  • Northwestern Medicine: Delnor — Geneva, Illinois
  • Northwestern University Oak Brook IL453 — Oak Brook, Illinois
  • Northwestern Medicine Orland Park — Orland Park, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

This phase II randomized control trial assesses the effect of Urolithin A (Uro-A) supplementation compared to placebo in men with biopsy-confirmed prostate cancer undergoing radical prostatectomy (RP) progressive disease. A total of 90 men…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06022822
Sites in Illinois:
  • Northwestern University — Chicago, Illinois
  • University of Chicago Comprehensive Cancer Center — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc

This trial tests if the combination of comprehensive metastasis directed therapy delivered by a precision form of external beam radiotherapy (stereotactic ablative radiotherapy), combined with PSMA targeted radiopharmaceutical therapy and …

Sponsor: VA Office of Research and Development
NCT ID: NCT06084338
Sites in Illinois:
  • Edward Hines Jr. VA Hospital, Hines, IL — Hines, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

This phase I/II tests the safety, side effects and best dose of ruxolitinib in combination with enzalutamide and how well it works in treating patients with prostate cancer that remains despite blocking hormone production (castration-resis…

Sponsor: University of Michigan Rogel Cancer Center
NCT ID: NCT06616155
Sites in Illinois:
  • Rush University — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

Sponsor: SystImmune Inc.
NCT ID: NCT05983432
Sites in Illinois:
  • Northwestern University Feinberg School of Medicine — Chicago, Illinois
View on ClinicalTrials.gov →

Showing 25 of 34 trials with sites in Illinois. See all prostate cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-01